NAV

Dexpramipexole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Dexpramipexole
DrugBank Accession Number
DB15130
Background

Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 211.33
Monoisotopic: 211.114318733
Chemical Formula
C10H17N3S
Synonyms
  • Dexpramipexole
External IDs
  • KNS-760704
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmisulprideThe therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Amisulpride.
AripiprazoleThe therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Aripiprazole.
Aripiprazole lauroxilThe therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Aripiprazole lauroxil.
AsenapineThe therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Asenapine.
BrexpiprazoleThe therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Brexpiprazole.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
WI638GUS96
CAS number
104632-28-2
InChI Key
FASDKYOPVNHBLU-SSDOTTSWSA-N
InChI
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m1/s1
IUPAC Name
(6R)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
SMILES
CCCN[C@@H]1CCC2=C(C1)SC(N)=N2

References

General References
Not Available
ChemSpider
54002
ChEMBL
CHEMBL249420
ZINC
ZINC000003831352
PharmGKB
PA164742949
Wikipedia
Dexpramipexole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
3TerminatedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)2
2CompletedTreatmentAsthma / Eosinophilic Asthma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.14 mg/mLALOGPS
logP2.18ALOGPS
logP1.76Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)17.66Chemaxon
pKa (Strongest Basic)10.31Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area50.94 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity59.77 m3·mol-1Chemaxon
Polarizability24.56 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0090000000-5bb3af51778261380cd5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0090000000-a167e14cd813f750232a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0390000000-ad9548caaff7e77ef83e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0390000000-f0111512206cbd0f2144
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fsr-1900000000-10e64efe5ca7fb35f1c6
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0007-1900000000-8a4c96caaadc9adae625
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-151.232993
predicted
DarkChem Lite v0.1.0
[M+H]+150.540493
predicted
DarkChem Lite v0.1.0
[M+Na]+151.779493
predicted
DarkChem Lite v0.1.0

Drug created at May 20, 2019 14:52 / Updated at December 01, 2022 11:29